ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.742,39
0,39%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. USOTC
  6. Sorrento Therapeutics Inc (CE) (SRNEQ)

  7. Sorrento Therapeutics Inc (CE) (SRNEQ) News

SRNEQ

Sorrento Therapeutics (CE) (SRNEQ)

Sorrento Therapeutics Inc (CE)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:USOTC:SRNEQ
DatumZeitQuelleÜberschriftSymbolFirma
07/11/202322h34Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SRNEQSorrento Therapeutics Inc (CE)
05/10/202323h26Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SRNEQSorrento Therapeutics Inc (CE)
05/10/202323h22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]USOTC:SRNEQSorrento Therapeutics Inc (CE)
05/10/202323h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesUSOTC:SRNEQSorrento Therapeutics Inc (CE)
26/09/202322h54Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SRNEQSorrento Therapeutics Inc (CE)
26/09/202322h49Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]USOTC:SRNEQSorrento Therapeutics Inc (CE)
25/09/202322h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesUSOTC:SRNEQSorrento Therapeutics Inc (CE)
21/08/202317h20Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SRNEQSorrento Therapeutics Inc (CE)
10/08/202322h14Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SRNEQSorrento Therapeutics Inc (CE)
18/07/202323h23Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementUSOTC:SRNEQSorrento Therapeutics Inc (CE)
08/07/202303h49Edgar (US Regulatory)Form 8-K - Current reportUSOTC:SRNEQSorrento Therapeutics Inc (CE)
21/06/202323h25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)USOTC:SRNEQSorrento Therapeutics Inc (CE)
20/06/202323h02Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
15/06/202315h44Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
19/05/202312h04Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
15/05/202321h18Edgar (US Regulatory)Quarterly Report (10-q)USOTC:SRNEQSorrento Therapeutics Inc (CE)
15/05/202318h04Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
12/05/202323h29Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)USOTC:SRNEQSorrento Therapeutics Inc (CE)
09/05/202312h03Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)USOTC:SRNEQSorrento Therapeutics Inc (CE)
03/05/202312h02Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
20/04/202323h28Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
20/04/202318h09Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
12/04/202314h51Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)USOTC:SRNEQSorrento Therapeutics Inc (CE)
10/04/202323h23Edgar (US Regulatory)Amended Current Report Filing (8-k/a)USOTC:SRNEQSorrento Therapeutics Inc (CE)
10/04/202321h16Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
31/03/202312h17Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
21/03/202300h54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:SRNEQSorrento Therapeutics Inc (CE)
20/03/202311h02Edgar (US Regulatory)Current Report Filing (8-k)USOTC:SRNEQSorrento Therapeutics Inc (CE)
10/03/202317h22Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:SRNEQSorrento Therapeutics Inc (CE)
08/03/202320h20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:SRNEQSorrento Therapeutics Inc (CE)
 Showing the most relevant articles for your search:USOTC:SRNEQ

Kürzlich von Ihnen besucht

BIT
P1TRA5
BNP Paribas Issuance
LSE
WHM
Whatman
ASX
DSQ
Datasquirt
TSX
ETHX.U
CI Galaxy Ethereum ETF
LSE
XU92
Citi Fun 26
BIT
UB8CFK
Unicredit Bank
BIT
P13ZQ9
BNP Paribas Issuance
USOTC
JLRRF
South Atlantic Gold (PK)
BITMOT
879211
Pech Green Mc Dc29 Amort...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten